Health Care [ 6/12 ] | Biotechnology [ 25/76 ]
NASDAQ | Common Stock
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 26 | -25.51 Decreased by -4.46 K% | -0.11 Decreased by -22.18 K% |
| Nov 5, 25 | -0.36 Decreased by -112.12% | -0.35 Decreased by -2.86% |
| Aug 14, 25 | -0.43 Increased by +60.55% | -0.90 Increased by +52.22% |
| May 13, 25 | -0.50 Increased by +55.75% | -1.07 Increased by +53.27% |
| Feb 25, 25 | -0.56 Increased by +59.71% | -1.05 Increased by +46.67% |
| Nov 5, 24 | 2.97 Increased by +388.35% | -1.01 Increased by +394.06% |
| Aug 6, 24 | -1.09 Increased by +2.68% | -0.97 Decreased by -12.37% |
| May 1, 24 | -1.13 Increased by +13.74% | -1.20 Increased by +5.83% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -283.67 M Decreased by -6.54 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -2.74 M Decreased by -112.19% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -3.26 M Increased by +60.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 42.22 K Increased by +N/A% | -3.75 M Increased by +56.20% | Decreased by -8.89 K% Decreased by N/A% |
| Dec 31, 24 | 42.22 K Increased by +N/A% | -4.27 M Increased by +52.65% | Decreased by -10.12 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | 22.51 M Increased by +387.88% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.23 M Decreased by -32.97% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.57 M Decreased by -22.93% | Decreased by N/A% Decreased by N/A% |